Scientists at Cerevance Inc. and Cerevance Ltd. have described potassium channel subfamily K member 13 (KCNK13; THIK-1) blockers reported to be useful for the treatment of fibrosis, depression, diabetes, gout, psoriasis, atherosclerosis, inflammatory bowel disease and traumatic brain injury.